We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
E. Magnus Ohman

E. Magnus Ohman MD, FRCPI, FESC, FACC, FSCAI

Professor of Medicine; The Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease; Associate Director, Duke Heart Center; Senior Investigator, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina

Dr. Ohman is Professor of Medicine, and received medical degrees from the Royal College of Surgeons in Ireland and the National University of Ireland, and completed his training in cardiology at Duke University, remaining on staff there.  In 2001, he became Chief of Cardiology at the University of North Carolina at Chapel Hill, where he founded the UNC Heart Center and became its first director.  In 2005 he returned to Duke to pursue his interest in advanced coronary disease as the Director of the Program for Advanced Coronary Disease.  In 2007, he became Associate Director of the Duke Heart Center, and in 2012, he became the Kent and Siri Rawson Director for the Program for Advanced Coronary Disease.

Dr. Ohman’s clinical and research interests include interventional cardiology and high-risk supported PCI, treatment of patients with advanced/complex coronary disease, improving patient care through the use of guidelines-based therapies and adherence, and examining global cardiovascular health.  His research has focused on ST-elevation myocardial infarction and reperfusion therapy, and antiplatelet and antithrombotic therapies.  He is a participant on numerous guidelines writing committees, serves on the ACC/AHA oversight committee for guidelines development, and has served on the steering committees for trials on ST-elevation myocardial infarction and non-ST-elevation ACS.   He is a consultant to the NIH, and a member of the FDA Advisory Panel for Cardiovascular Devices. 

Dr. Ohman has published over 500 peer-reviewed papers and three books in cardiovascular medicine.  He holds three U.S. patents in reperfusion therapy.  He is an associate editor for the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the American Journal of Cardiology.  He is a Fellow of the Royal College of Physicians in Ireland, the Royal Society of Medicine (U.K.), the European Society of Cardiology, the Society of Cardiac Angiography and Interventions, and the American College of Cardiology. 

Disclosures

  1. Served as Senior Investigator for Duke Clinical Research Institute (DCRI) in a Scientific Study or Trial with: Daiichi Sankyo
  2. Served as Senior Investigator for Duke Clinical Research Institute (DCRI) in a Scientific Study or Trial with: Eli Lilly & Company
  3. Served as Senior Investigator for Duke Clinical Research Institute (DCRI) in a Scientific Study or Trial with: Gilead Sciences
  4. Salary partially supported by Research Grant or Contract with: Daiichi Sankyo
  5. Salary partially supported by Research Grant or Contract with: Eli Lilly & Company
  6. Salary partially supported by Research Grant or Contract with: Gilead Sciences
  7. Serve(d) as Consultant/Advisor or Lecturer with: Abiomed
  8. Serve(d) as Consultant/Advisor or Lecturer with: AstraZeneca
  9. Serve(d) as Consultant/Advisor or Lecturer with: Daiichi Sankyo
  10. Serve(d) as Consultant/Advisor or Lecturer with: Eli Lilly & Company
  11. Serve(d) as Consultant/Advisor or Lecturer with: Gilead Sciences
  12. Serve(d) as Consultant/Advisor or Lecturer with: Janssen Pharmaceuticals (Johnson & Johnson)
  13. Serve(d) as Consultant/Advisor or Lecturer with: Pozen, Inc.
  14. Serve(d) as Consultant/Advisor or Lecturer with: Sanofi Aventis
  15. Serve(d) as Consultant/Advisor or Lecturer with: The Medicines Company
  16. Serve(d) as Advisor, Writer, or Reviewer with: WebMD